TSMC denies U.S. is probing the company after report suggests blacklisted Huawei is using its chips
TSMC has denied a report that the U.S. is investigating its dealings with Huawei, following news that one of its chips has been found in a Huawei product.
Zelenskyy calls on allies ‘not to hide,’ respond to North Korean involvement in war
Ukrainian President Volodymyr Zelenskyy urged allies on Tuesday “not to hide” and to respond to proof of North Korean involvement in Russia’s war in Ukraine.
Tokyo Metro shares gain almost 45% on debut after Japan’s largest IPO in six years
The IPO offered 2.32 billion shares for a price of 1,200 yen apiece, valuing the offering at 348.6 billion yen ($2.3 billion)
Tokyo Metro shares surge 45% on debut after Japan’s largest IPO in six years
The IPO offered 2.32 billion shares for a price of 1,200 yen apiece, valuing the offering at 348.6 billion yen ($2.3 billion)
IMF warns on China’s property market worsening as it cuts country’s growth outlook
In a report published Tuesday, the IMF trimmed its forecast for growth in China for this year to 4.8%, 0.2 percentage points lower than in its July projection.
IMF warns on China’s property market worsening as it cuts country’s growth outlook
In a report published Tuesday, the IMF trimmed its forecast for growth in China for this year to 4.8%, 0.2 percentage points lower than in its July projection.
CNBC Daily Open: The S&P could still have legs despite stalling
With elections and high valuations, the path ahead for markets may be rocky. But the S&P might persist in scaling an ever-ascending mountain range.
CNBC Daily Open: The S&P could still have legs despite stalling
With elections and high valuations, the path ahead for markets may be rocky. But the S&P might persist in scaling an ever-ascending mountain range.
Asia stocks mostly rise after Wall Street rally stalls; Tokyo Metro shares soar on debut
Tokyo Metro raised $2.32 billion in its IPO, with shares priced at 1,200 yen apiece.
FDA approves Pfizer’s RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer’s RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
